Sign up
Pharma Capital

C4X Discovery preparing to do something 'very different' in drug development

Clive Dix, chief executive of C4X Discovery Holdings plc, (LON:C4XD) brings Proactive up to speed on developments with the firm's portfolio of drug candidates.

They've recently presented some pre-clinical data at a leading industry conference which they say strengthens the evidence base backing the potential of the anti-addiction drug Orexin-1.

It's being developed to target the craving process and therefore is expected to be used across a broad range of substance disorders.

The latest study assessed nicotine self-administration and cue-induced reinstatement; the latter is where strong cravings are triggered by an object or ritual closely associated with taking an addictive substance.

 

View full C4XD profile

C4X Discovery Holdings plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.